Features | Partner Sites | Information | LinkXpress
Sign In
Bio-Rad Diabetes Division
RANDOX LABORATORIES
PURITAN MEDICAL

Digital PCR Chosen to Develop Leukemia Test

By Labmedica International staff writers
Posted on 04 Feb 2013
A general method called “limiting dilution polymerase chain reaction (PCR)” was developed for quantifying PCR targets. This method was subsequently used for the quantification of marker mutations in acute leukemia.

By diluting DNA samples so that only one or two copies per well were present and then amplifying those copies with PCR, scientists were able to detect two copies of leukemic DNA against a background of 160,000 normal genomes.

The team then reported that the outcome of acute leukemia can be predicted by measuring the response to treatment using limiting dilution PCR to quantify the leukemic cells at high sensitivity. Prof. Alec Morley and his lab at Flinders University and Medical Center in Adelaide (SA, Australia) then used real-time quantitative PCR (qPCR) to develop a highly sensitive method for isolating and quantifying the chromosomal translocation that is typically associated with chronic myelogenous (or myeloid) leukemia (CML), also known as chronic granulocytic leukemia (CGL), a cancer of the white blood cells. It is a form of leukemia characterized by the increased and unregulated growth of predominantly myeloid cells in the bone marrow and the accumulation of these cells in the blood.

Because the translocation point for each patient is different in CML, real-time PCR conditions may vary from patient to patient and may therefore produce different results. Therefore, real-time PCR conditions may vary from patient to patient and may therefore produce different results. The lab has now returned to digital PCR.

Monoquant, a company associated with Flinders University, used Bio-Rad’s (Hercules, CA, USA) QX100 system to refine the new clinical test for CML. Not only does the instrument offer high sensitivity but also removes variability in amplification efficiency that results from using patient-specific PCR primers, a traditional sticking point for the US Food and Drug Administration (FDA; Silver Spring, MD, USA). Monoquant hopes the results from the QX100 system will fast-track the FDA approval process for its test.

Related Links:
Flinders University and Medical Center in Adelaide, South Australia
Monoquant
Bio-Rad




KARL HECHT GMBH & CO KG
ADVANCED INSTRUMENTS
DIASYS DIAGNOSTIC SYSTEMS
WATERS CORPORATION

Channels

Genetic Tests

view channel

Overexpression of X Chromosome Genes Is Biomarker for Female Mental Disorders

A recent paper suggested that elevated expression of the genes XIST (X-inactive specific transcript) and KDM5C (lysine-specific demethylase 5C) could be used as a biological marker for diagnosis of major affective disorders in a significantly large subset of female patients from the general population. Xist is an RNA... Read more

Immunology

view channel

Powerful Innovations in Diagnostics Unveiled at EuroMedLab 2015

New systems presented by Roche include a new standard for immunology testing, an integrated platform for hematology diagnostics, and a high-throughput analyzer to perform HbA1c tests for blood glucose management. Also, evidence was presented for a high-sensitivity cardiac troponin test to provide earlier and more accurate... Read more

Industry News

view channel

Cloud-Based Systems Becoming Key Pillar in eHealth Strategy

Cloud-based laboratory information management systems (LIMS) are becoming a key pillar in Europe’s e-Health strategy as data-management solutions for modern testing will generate more demand for these systems. Investments in cloud-based LIMS are part of Europe’s e-Health strategy. New analysis from Frost & Sullivan... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.